Navigation Links
BD Biosciences Launches BD FACSAria(TM) III Flow Cytometry System
Date:2/23/2010

SAN JOSE, Calif., Feb. 23 /PRNewswire-FirstCall/ -- BD Biosciences, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), announced today the launch of the BD FACSAria™ III Cell Sorting System, a next-generation flow cytometer with the ability to run complex multicolor experiments using up to six lasers.

"As the pioneer in flow cytometry, BD Biosciences' goal is to expand the range of applications that can benefit from this technology by building innovative, powerful tools that are easier to use and more accessible to a larger number of life science researchers," said James Glasscock, President, BD Biosciences – Cell Analysis.  "The new BD FACSAria III system reflects this effort by providing researchers the flexibility to configure a system that meets their application requirements and budgets today, with the ability to expand its capabilities later to meet future needs."

Innovations in the new BD FACSAria III Cell Sorting System include:

  • A next-generation gel coupled cuvette in the flow cell ensures that the system's lasers are focused precisely on the sample stream and that they generate the greatest signal to maximize the amount of emitted light.  Most importantly, it improves collection efficiency and optimizes the resolution needed for multicolor applications, even at high-speed sorting settings.
  • The instrument's advanced optical system works efficiently to maximize signal detection as well as greatly increase the sensitivity and resolution for each color in a multicolor assay. Enhanced sensitivity and resolution helps readily identify and sort dim cell populations.  In addition, the system's next-generation flow cell is designed to improve resolution for side population applications and DNA cell cycle analyses.
  • A new expandable architecture uses an X-mount optical plate that allows the system to be expanded to support up to six laser wavelengths — 633 nm, 561 nm, 488 nm, 445 nm, 405 nm and 375 nm — as well as up to 20 detector positions that can be used simultaneously.
  • A backwards-compatible architecture allows customers to upgrade existing instruments to the new BD FACSAria III platform.  With a field upgrade, laboratories with a BD FACSAria or BD FACSAria II system can upgrade to the new capabilities of the BD FACSAria III system.  

For more information on the BD FACSAria III Cell Sorting System, please visit:  www.bdbiosciences.com/aria

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

SOURCE BD-Becton Dickinson

Back to top

RELATED LINKS
http://www.bd.com

'/>"/>

SOURCE BD-Becton Dickinson
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hollis-Eden Announces Name Change to Harbor BioSciences, Inc. and Ticker Symbol Change to HRBR
2. Sangamo BioSciences Announces Fourth Quarter and Full Year 2009 Conference Call and Webcast
3. Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications
4. Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium
5. Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference
6. CeloNova BioSciences CEO Urges More Heart, More Passion, More Honesty, and All Urgency in Developing Medical Devices
7. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
8. Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting
9. Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
10. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
11. Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 4, 2016 Frontier Pharma: Chronic Obstructive ... Innovation Chronic Obstructive Pulmonary Disease ... inflammation of the airways and lungs. Persistent breathing ... the disease one of the leading causes of ... the world. COPD is linked to cumulative exposure ...
(Date:2/4/2016)... Feb. 4, 2016  Aethlon Medical, Inc. (Nasdaq: ... biofiltration devices to treat life-threatening diseases, today announced ... ended December 31, 2015. --> ... set forth in our last quarterly call, we ... our long-term objective to establish the Aethlon Hemopurifier® ...
(Date:2/4/2016)...  Blueprint Medicines Corporation (NASDAQ: BPMC ), ... investigational kinase medicines for patients with genomically defined ... of directors of Lonnel Coats , a ... industry-related experience. Jeffrey Albers , ... strategic experience developing and commercializing numerous oncology products ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... February 06, 2016 , ... Shark Finds ... the launch of a new DRTV campaign with Belly Bands. , Having a dog ... from sprays to puppy pads and find nothing works, get Belly Bands, the ...
(Date:2/5/2016)... Toronto, Ontario (PRWEB) , ... February 05, 2016 ... ... today announced the availability of the company's lighter, sleeker next generation LYNX VR ... assembly plant. , Improvements in design and manufacturing not only reduce the ...
(Date:2/5/2016)... ... 05, 2016 , ... The Muscular Dystrophy Association and Sailormen ... the 14th annual “Appetite for a Cure” campaign on Feb. 1 to raise ... related diseases that severely limit strength and mobility. , Now through March ...
(Date:2/5/2016)... ... 05, 2016 , ... After years as an active staff surgeon and having ... surgeon Dr. Wayne Carman transitioned to chief of the Division of Plastic Surgery at ... term as chief and began a second three-year term in January of 2016. , ...
(Date:2/5/2016)... ... February 05, 2016 , ... The American public tends to ... may be safer than regular municipal or well water. The recent experience with lead ... Kleyne, could go a long way toward increasing public acceptance of recycled waste water ...
Breaking Medicine News(10 mins):